Optic Neuritis

Educational clinical summary of Optic Neuritis for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment. Clinicians must use their professional judgment in applying this information to individual patient care, considering the patient's specific circumstances, current evidence, and local guidelines. Always consult with a qualified healthcare professional for diagnosis and treatment decisions.

Overview

Definition: Optic neuritis (ON) is an acute inflammatory demyelinating disorder affecting the optic nerve, characterized by subacute vision loss, often accompanied by orbital pain. It is a common initial manifestation of multiple sclerosis (MS) but can also be idiopathic or associated with other autoimmune or inflammatory conditions.
Epidemiology:
- Incidence: Estimated at 1-5 per 100,000 population per year.
- Prevalence: More common in young adults, typically between 20 and 50 years of age.
- Sex: Approximately 2-3 times more common in women than men, reflecting the epidemiology of MS.
- Geography/Ethnicity: Higher incidence in populations with higher rates of MS (e.g., Caucasians of Northern European descent).
- Association with MS: Approximately 50% of patients with MS will experience ON during their disease course. Conversely, a substantial percentage (50-70% over 15 years) of patients presenting with isolated ON will eventually develop MS, especially if brain lesions are present on MRI at the time of ON.
Classification:
- Typical Optic Neuritis:
  - Demyelinating/Idiopathic: The most common form, often presumed to be immune-mediated.
  - MS-associated: Occurs in patients with established MS or as the initial demyelinating event (clinically isolated syndrome, CIS) that may progress to MS.
  - Clinical Characteristics: Usually unilateral, painful eye movements, subacute vision loss, good prognosis for visual recovery, often retrobulbar (normal fundus) but can be papillitis (optic disc swelling).
- Atypical Optic Neuritis: Suggests an underlying systemic or specific autoimmune condition, often with different clinical courses and prognoses. Red flags for atypical ON include:
  - Severe or bilateral vision loss (light perception or no light perception).
  - Lack of pain.
  - Recurrent ON in the same eye.
  - Concurrent myelitis or other neurological symptoms.
  - Absence of a relative afferent pupillary defect (RAPD) in unilateral severe vision loss.
  - Specific causes include:
    - Neuromyelitis Optica Spectrum Disorder (NMOSD): Characterized by autoantibodies to aquaporin-4 (AQP4-IgG). Often severe, bilateral, or recurrent, with poorer visual outcomes and frequently associated with myelitis.
    - Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Characterized by autoantibodies to MOG-IgG. Can cause bilateral or recurrent ON, often with disc edema, and may be associated with encephalomyelitis. Visual recovery can vary.
    - Systemic Autoimmune Diseases: e.g., Systemic lupus erythematosus (SLE), sarcoidosis, Sjögren's syndrome, Behçet's disease.
    - Infectious Causes: Syphilis, Lyme disease, cat-scratch disease, viral infections (e.g., VZV, HSV, HIV).
    - Paraneoplastic Optic Neuropathy.

Pathophysiology

Mechanism: Optic neuritis is primarily an inflammatory demyelinating process affecting the optic nerve.
- Immune-mediated Demyelination: In MS-associated ON, it is thought to be a T-cell mediated autoimmune attack against myelin components in the optic nerve, leading to myelin sheath destruction and subsequent axonal damage. This disrupts saltatory conduction, causing signal slowing and block.
- Axonal Damage: While primarily demyelinating, significant axonal injury also occurs, contributing to permanent visual deficits and optic atrophy. Mitochondrial dysfunction may also play a role in axonal vulnerability.
- Inflammation and Edema: Inflammatory cells (lymphocytes, macrophages) infiltrate the optic nerve, causing swelling (edema) and disrupting the blood-brain barrier.
- AQP4-IgG (NMOSD): In NMOSD, AQP4-IgG antibodies bind to aquaporin-4 water channels on astrocytes, leading to complement activation, astrocyte injury, and severe inflammation, demyelination, and axonal loss, often more extensive than typical ON.
- MOG-IgG (MOGAD): In MOGAD, MOG-IgG antibodies target myelin oligodendrocyte glycoprotein on the surface of oligodendrocytes, leading to demyelination. The exact mechanism of tissue damage is still being elucidated but involves antibody-dependent cellular cytotoxicity and complement activation.
Risk Factors:
- Genetic Predisposition: Presence of HLA-DRB1*15:01 allele is strongly associated with MS and ON.
- Environmental Factors:
  - Low Vitamin D Levels: Associated with increased risk of MS.
  - Smoking: Increases the risk of MS and potentially ON.
  - Viral Infections: Epstein-Barr virus (EBV) infection has been implicated in MS pathogenesis.
- Female Sex: Higher incidence in women.
- Age: Young to middle adulthood (20-50 years).
- Existing Autoimmune Conditions: Patients with other autoimmune diseases (e.g., SLE, sarcoidosis) are at higher risk for atypical ON.
Protective Factors:
- No specific protective factors for ON are definitively established.
- General health measures that reduce MS risk (e.g., adequate vitamin D levels, not smoking) may indirectly reduce ON risk.

Clinical Presentation

Signs and Symptoms

Cardinal Features:
- Acute or Subacute Vision Loss: Typically monocular, developing over hours to days (usually <2 weeks). Severity can range from mild blurring to no light perception (NLP).
- Orbital Pain: Present in >90% of typical ON cases. Described as a dull ache behind the eye, often worsened by eye movement (especially adduction or abduction). Precedes vision loss in about 50% of cases.
- Dyschromatopsia: Impaired color vision, particularly red desaturation, often out of proportion to the decrease in visual acuity. This is a highly sensitive sign.
- Phosphenes: Flashing lights, especially with eye movement or sound (Uhthoff's phenomenon).
- Uhthoff's Phenomenon: Worsening of visual symptoms with an increase in body temperature (e.g., exercise, hot bath).
- Pulfrich Phenomenon: Objects moving in a straight line appear to move in an elliptical or circular path (due to delayed signal conduction in the affected eye).
Early Signs:
- Mild blurring or "graying out" of vision.
- Subtle orbital discomfort or pain with eye movement.
- Mild red desaturation.
Advanced Signs:
- Profound vision loss (counting fingers, hand motion, light perception, or no light perception).
- Severe pain or persistent pain even without eye movement (less typical for ON).
- Marked optic disc pallor (if chronic/recurrent).
Atypical Presentations: These features should raise suspicion for NMOSD, MOGAD, or other causes requiring further investigation.
- Bilateral simultaneous ON.
- Rapidly progressive and severe vision loss (NLP).
- Lack of pain.
- Absence of improvement or worsening despite corticosteroid treatment.
- Recurrent ON in the same eye.
- Concurrent myelitis, brainstem, or cerebral symptoms (suggests NMOSD/MOGAD).
- Optic disc edema (papillitis) more commonly seen in pediatric ON or MOGAD.
- Persistent fever, headache, meningismus.

Physical Examination

Inspection:
- Visual Acuity: Measured using a Snellen chart. Ranges from 20/20 to no light perception.
- Color Vision: Tested using Ishihara or Hardy-Rand-Rittler pseudoisochromatic plates. Red desaturation can be tested by comparing the vibrancy of a red object between the two eyes.
- Pupillary Examination:
  - Relative Afferent Pupillary Defect (RAPD) or Marcus Gunn pupil: Present in unilateral or asymmetric bilateral ON. The affected pupil dilates paradoxically when light is swung from the unaffected to the affected eye. This is a critical diagnostic sign.
  - Absence of RAPD: May occur in bilateral symmetric ON or if vision loss is mild.
- Funduscopic Examination:
  - Retrobulbar ON: The most common presentation (2/3 of cases). The optic nerve head (fundus) appears normal acutely because the inflammation is behind the globe. "The patient sees nothing, and the doctor sees nothing."
  - Papillitis: Optic disc swelling (edema) is present in about 1/3 of cases, indicating inflammation of the intraocular portion of the optic nerve. Margins are blurred, and veins may be engorged. Distinguish from papilledema (bilateral, usually preserved vision, due to increased ICP).
  - Optic Atrophy: Late finding (weeks to months after onset) characterized by pallor of the optic disc, particularly the temporal aspect, indicating axonal loss.
- Ocular Motility: May show restricted movement due to pain.
Palpation: Not typically performed for diagnosis, but orbital tenderness may be noted if palpating around the globe.
Special Tests:
- Visual Field Testing: Can reveal various defects, including central, centrocecal, arcuate, or altitudinal scotomas. Formal perimetry (e.g., Humphrey visual field) provides detailed mapping of visual field loss.
- Contrast Sensitivity Testing: Often reduced, even if visual acuity is relatively preserved.
- Optical Coherence Tomography (OCT): Measures retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness. Can detect subtle or subclinical axonal loss and monitor for progression of atrophy after an ON event.

Diagnostic Approach

History Taking

Key Questions:
- Onset and Course: When did vision loss begin? Was it sudden or gradual? How quickly did it progress? Has it improved or worsened?
- Associated Symptoms: Pain with eye movement? Location and character of pain? Color vision changes (especially red desaturation)? Flashing lights?
- Laterality: Unilateral or bilateral?
- Previous Episodes: Any prior episodes of vision loss, numbness, weakness, imbalance, double vision, or bladder dysfunction? (suggests MS)
- Systemic Symptoms: Fever, headache, weight loss, joint pain, skin rash, oral ulcers, shortness of breath, dry eyes/mouth? (suggests systemic inflammatory/autoimmune disease)
- Medical History: History of autoimmune diseases (e.g., SLE, sarcoidosis), recent infections, diabetes, hypertension.
- Medications: Including any immunosuppressants.
- Family History: MS or other autoimmune diseases.
Red Flags:
- Bilateral acute, severe vision loss (NLP): Highly suspicious for atypical ON (NMOSD, MOGAD) or severe compressive/ischemic etiologies.
- Absence of pain with eye movement: Less typical for ON, raising suspicion for other optic neuropathies (e.g., ischemic optic neuropathy).
- Lack of improvement or worsening within 2 weeks after steroid treatment.
- Profound vision loss (e.g., 20/200 or worse) at nadir.
- Significant optic disc edema (papillitis), especially if bilateral.
- Concurrent neurological symptoms beyond ON: e.g., weakness, sensory loss, bladder dysfunction, cerebellar signs (suggests NMOSD, MOGAD, MS).
- Age <10 or >50 years: Consider alternative diagnoses (e.g., infectious, metabolic, ischemic, compressive).

Laboratory Tests

First-Line (Considered in atypical cases or for MS risk stratification):
- Aquaporin-4 (AQP4-IgG) Antibody: Test for NMOSD, especially in severe, bilateral, or recurrent ON, or when associated with myelitis.
- Myelin Oligodendrocyte Glycoprotein (MOG-IgG) Antibody: Test for MOGAD, especially in cases of bilateral ON, severe disc edema, recurrent ON, or pediatric ON.
- Cerebrospinal Fluid (CSF) Analysis (Lumbar Puncture):
  - Oligoclonal Bands (OCBs): Presence of OCBs in CSF but not in serum is a strong predictor of MS development after CIS. Present in >90% of definite MS patients. Their absence may reduce MS risk but does not rule it out.
  - IgG Index: Elevated in MS.
  - Cell Count and Protein: Typically mildly elevated in ON (up to 50 mononuclear cells/µL, protein <100 mg/dL). Higher counts or presence of neutrophils suggest infectious or other inflammatory causes.
- Routine Blood Work (If systemic inflammation or infection suspected):
  - Complete Blood Count (CBC) with differential.
  - Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP).
  - Antinuclear Antibody (ANA), Extractable Nuclear Antigen (ENA) panel (if SLE suspected).
  - Angiotensin-Converting Enzyme (ACE) levels (if sarcoidosis suspected).
  - Syphilis serology (VDRL/RPR, FTA-ABS), Lyme titers (if endemic).
  - HIV testing.
Confirmatory: There is no single "confirmatory" lab test for typical ON. Diagnosis is clinical with imaging support. AQP4-IgG or MOG-IgG antibodies confirm NMOSD or MOGAD respectively.
Monitoring: For atypical ON, antibody titers may be monitored in some cases (e.g., MOGAD) to guide treatment. For MS, regular neurological and ophthalmological follow-up is essential.

Imaging

Recommended:
- Brain Magnetic Resonance Imaging (MRI) with Gadolinium and Fat Suppression: Essential for all patients presenting with a first episode of ON to assess the risk of developing MS and to rule out alternative diagnoses (e.g., compressive lesions, sinusitis).
  - Optic Nerve: High-resolution, fat-suppressed T2-weighted and post-gadolinium T1-weighted sequences are crucial. In acute ON, typically shows T2 hyperintensity and gadolinium enhancement of the affected optic nerve.
  - Brain Lesions: Search for T2-hyperintense lesions characteristic of MS (e.g., ovoid lesions in the periventricular, juxtacortical, infratentorial regions, and corpus callosum, often perpendicular to the lateral ventricles - "Dawson's fingers").
    - Risk of MS: If ≥2 typical MS lesions are found on baseline MRI, the risk of developing clinically definite MS within 15 years is ~72%. If no lesions, the risk is ~25%.
- Optical Coherence Tomography (OCT): Useful for objective measurement of retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thickness, serving as a biomarker for axonal damage and a baseline for monitoring for subsequent atrophy.
Advanced:
- Spinal Cord MRI: Recommended if myelitis (spinal cord inflammation) is suspected (e.g., motor weakness, sensory changes, bowel/bladder dysfunction), especially in the context of atypical ON or NMOSD.
- Visual Evoked Potentials (VEPs): Can demonstrate delayed P100 latency, confirming demyelination in the visual pathway. Useful in cases of subtle or equivocal symptoms, or to detect subclinical ON in the contralateral eye.

Management

Acute Management

Immediate:
- Confirm diagnosis and exclude red flags for atypical ON.
- Assess vision and neurological status.
- Consider inpatient admission for severe cases, significant comorbidities, or diagnostic workup requiring prompt attention (e.g., rapid rule-out of giant cell arteritis in older patients).
Stabilization:
- High-Dose Intravenous Corticosteroids: Based on the Optic Neuritis Treatment Trial (ONTT) findings, IV methylprednisolone is the first-line treatment for typical ON.
  - Regimen: Methylprednisolone 1 gram IV daily for 3 days, followed by an oral prednisone taper of 1 mg/kg/day (up to 60-80 mg/day) for 11 days. Total steroid course is 14 days.
  - Benefit: Accelerates visual recovery (patients recover vision faster), but does not improve the final visual outcome at 1 year compared to placebo.
  - Prevention of MS: In patients with ON and abnormal brain MRI (i.e., MS-like lesions), IV methylprednisolone followed by oral prednisone reduced the 2-year risk of developing clinically definite MS (CDMS) from 50% to 25%. This benefit was not sustained at 3-5 years.
  - Contraindication: Oral prednisone alone (without prior IV treatment) is contraindicated as it was associated with a higher rate of new ON episodes in the ONTT.
- Symptomatic Management: Address pain with analgesics.
Emergency:
- Acute, severe vision loss, especially if bilateral, necessitates rapid evaluation to rule out other causes that may require emergent intervention (e.g., giant cell arteritis in older patients, compressive lesions). Consider empirical IV steroids while workup is ongoing in such cases.
- Plasma exchange (PLEX) for severe, steroid-unresponsive atypical ON (e.g., NMOSD/MOGAD).

Chronic Management

Pharmacological:
- Disease-Modifying Therapies (DMTs) for MS:
  - If the patient meets criteria for MS (e.g., McDonald criteria) or has a clinically isolated syndrome (CIS) with high risk of MS (e.g., two or more brain lesions on MRI at time of ON), initiation of a DMT for MS should be considered to reduce the risk of future relapses and disease progression.
  - Choice of DMT depends on disease activity, patient comorbidities, preference, and tolerability.
- Long-term Immunosuppression for Atypical ON:
  - NMOSD (AQP4-IgG positive): Long-term treatment with agents such as rituximab, eculizumab, satralizumab, or inebilizumab is crucial to prevent relapses, which are often severe and cause cumulative disability.
  - MOGAD (MOG-IgG positive): Long-term immunosuppression (e.g., oral corticosteroids, azathioprine, mycophenolate mofetil, rituximab, or IVIg) is often required to prevent recurrent attacks, though duration of treatment is an area of ongoing research.
  - Other Autoimmune Causes: Management of the underlying systemic condition (e.g., sarcoidosis, SLE) with appropriate immunosuppressants.
Non-pharmacological:
- Low Vision Aids: Magnifiers, adaptive technology for persistent vision loss.
- Rehabilitation: Occupational therapy, physical therapy, and psychological support if there are other neurological symptoms or significant impact on daily life.
- Patient Education: Provide information about the condition, potential for MS development, and the importance of adherence to follow-up and treatment.
Monitoring:
- Regular Ophthalmological Follow-up: To assess visual acuity, color vision, visual fields, and monitor for optic atrophy via fundus exam and OCT.
- Neurological Follow-up: For patients at risk of or diagnosed with MS, to monitor for new neurological symptoms, relapses, and disease progression.
- Repeat MRI: Performed as per MS guidelines (e.g., annually or biennially, or if new symptoms arise) to monitor for new lesions or disease activity, particularly if on a DMT.

Treatment Algorithms

First-Line (Typical Demyelinating ON):
1. Confirm diagnosis clinically and with MRI brain (including optic nerve sequences).
2. Administer high-dose IV methylprednisolone (1g IV daily for 3 days).
3. Follow with oral prednisone taper (1 mg/kg/day, max 60-80 mg, for 11 days).
4. Counsel on MS risk based on MRI findings. Consider DMT if criteria for MS are met or patient is high-risk CIS.
Second-Line (Atypical/Severe/Steroid-Refractory ON):
1. Investigate for atypical causes (AQP4-IgG, MOG-IgG, CSF, systemic workup).
2. Plasma Exchange (PLEX): Consider for severe, steroid-unresponsive ON, especially in NMOSD or MOGAD, often initiated after 3-5 days of IV steroids if no improvement.
3. Treat underlying specific cause with appropriate long-term immunosuppression (e.g., NMOSD, MOGAD, sarcoidosis).
Refractory Cases:
- For ON in the context of NMOSD or MOGAD that does not respond to corticosteroids and PLEX, other immunosuppressive agents may be considered on a case-by-case basis (e.g., cyclophosphamide), often in consultation with neuro-ophthalmology or neuroimmunology specialists.

Complications

Common:
- Residual Visual Deficits: While most patients recover good visual acuity, subtle deficits often persist, including reduced contrast sensitivity, color desaturation (especially red), and mild blurriness.
- Optic Disc Pallor (Optic Atrophy): A common sequela, particularly temporal pallor, indicating permanent axonal loss.
- Recurrent Optic Neuritis: Can occur in the same or contralateral eye. More common in patients who develop MS, NMOSD, or MOGAD.
Serious:
- Development of Multiple Sclerosis (MS): The most significant long-term risk. Patients with an abnormal baseline brain MRI (MS-like lesions) have a ~72% risk of developing CDMS within 15 years.
- Severe Permanent Vision Loss: Although most typical ON cases recover well, some patients, particularly those with atypical ON (NMOSD, MOGAD) or recurrent attacks, can experience profound and permanent vision loss in the affected eye(s).
Long-term:
- Impact on Quality of Life: Residual visual deficits, chronic pain, and the uncertainty of developing MS can significantly affect a patient's quality of life, leading to anxiety, depression, and functional limitations.
- Fatigue and Cognitive Dysfunction: Common symptoms associated with MS, even in its early stages.

Prognosis

Factors Affecting Outcome:
- Visual Acuity at Nadir: Poorer initial visual acuity (e.g., light perception or worse) is associated with a worse final visual outcome.
- Type of ON: Typical demyelinating ON generally has a good prognosis for visual recovery. Atypical ON (NMOSD, MOGAD) often carries a higher risk of severe, permanent vision loss and recurrence.
- Brain MRI at Presentation: Presence of MS-like brain lesions increases the risk of developing MS.
- Treatment: IV corticosteroids accelerate visual recovery but do not influence final visual acuity. Early treatment of underlying conditions like NMOSD or MOGAD can prevent cumulative damage.
Visual Recovery:
- Typical ON: Approximately 90% of patients with typical ON recover visual acuity of 20/40 or better within 1 year, even without treatment. Visual recovery typically begins within 2-4 weeks and continues for up to 6-12 months.
- Atypical ON: Prognosis for visual recovery is generally poorer in NMOSD and MOGAD, with a higher likelihood of significant residual visual impairment after attacks.
Survival: Optic neuritis itself is not a direct cause of mortality. Prognosis for survival is related to the underlying condition (e.g., MS, NMOSD, MOGAD) and its long-term impact on neurological function.
Quality of Life: Can be significantly impacted by persistent visual deficits, chronic fatigue, pain, and the psychological burden of a potential MS diagnosis or other neuroinflammatory conditions.

Prevention

Primary Prevention:
- No specific measures for primary prevention of typical ON are established.
- For MS, maintaining adequate vitamin D levels and avoiding smoking are general recommendations that may reduce overall MS risk.
Secondary Prevention:
- Early Diagnosis and Treatment: Prompt recognition of ON and appropriate corticosteroid treatment (IV methylprednisolone) can speed visual recovery.
- MS Risk Stratification: All patients with a first episode of ON should undergo brain MRI to assess the risk of developing MS.
- Disease-Modifying Therapy (DMT) for High-Risk CIS: For patients with CIS (including ON) who have brain lesions suggestive of MS on MRI, initiating a DMT can reduce the risk of conversion to clinically definite MS and decrease the frequency of subsequent relapses.
- Long-term Immunosuppression for Atypical ON: Early and continuous immunosuppression for NMOSD and MOGAD is critical to prevent relapses and cumulative disability.
Tertiary Prevention:
- Managing Underlying Disease: Meticulous long-term management of MS or other associated conditions (e.g., NMOSD, MOGAD) to prevent further attacks and minimize neurological disability.
- Rehabilitation and Support: Providing low vision aids, occupational therapy, and psychological support to optimize functional outcomes and quality of life for those with residual deficits.

Special Populations

Pediatric:
- Presentation: Pediatric ON is more often bilateral (up to 30% of cases) and associated with disc edema (papillitis) than adult ON. Visual recovery tends to be better.
- Atypical ON: Atypical ON, particularly MOGAD, is more common in children than adults with ON. NMOSD can also occur.
- MS Risk: Children with ON have a significant risk of developing MS, similar to adults.
- Treatment: High-dose IV corticosteroids are generally used, similar to adults. PLEX may be considered for severe steroid-refractory cases.
Geriatric:
- Prevalence: ON is less common in individuals >50 years.
- Differential Diagnosis: In older adults, other causes of acute vision loss are more likely, including ischemic optic neuropathy (e.g., giant cell arteritis, non-arteritic ischemic optic neuropathy), compressive lesions, and glaucoma. Giant cell arteritis (GCA) is a medical emergency requiring immediate high-dose steroid treatment.
- Atypical Presentation: May present more subtly or with different accompanying symptoms.
- Treatment: Corticosteroid use requires careful consideration due to potential comorbidities and side effects (e.g., diabetes, hypertension, osteoporosis).
Pregnancy:
- Incidence: ON can occur during pregnancy or postpartum. Pregnancy itself may offer some protective effect against MS relapses, but the postpartum period carries an increased risk.
- Management: Acute ON during pregnancy is generally treated with high-dose IV methylprednisolone, as the benefits of preserving vision typically outweigh the risks. Oral prednisone should be used with caution, particularly in the first trimester.
- DMTs: Long-term DMTs for MS need careful discussion regarding safety profiles during pregnancy and lactation. Some DMTs are considered safer than others, or may be temporarily discontinued.
Comorbidities:
- Diabetes and Hypertension: These conditions increase the risk of ischemic optic neuropathy, which can mimic ON. Careful differentiation is necessary.
- Other Autoimmune Diseases: Patients with known autoimmune conditions (e.g., SLE, sarcoidosis) require a targeted workup for atypical ON. Treatment often involves managing the underlying systemic disease.
- Immunosuppression: Patients already on immunosuppressants for other conditions may have an altered immune response to ON or may be at higher risk for opportunistic infections that can cause optic neuropathy.

Clinical Pearls

Diagnostic:
- "Pain with eye movement + vision loss = Optic Neuritis until proven otherwise." This combination is highly characteristic.
- Always check for a Relative Afferent Pupillary Defect (RAPD). This is a crucial objective sign of unilateral optic nerve dysfunction.
- Remember the "normal fundus" in retrobulbar ON: Over two-thirds of ON cases show a normal optic disc on funduscopic exam acutely. Don't let a normal fundus mislead you.
- Don't miss atypical ON: Severe, bilateral, or painless vision loss, or recurrent ON in the same eye, should trigger a workup for AQP4-IgG and MOG-IgG antibodies.
- MRI is mandatory: Brain MRI with gadolinium and optic nerve sequences is essential for diagnosis, ruling out other causes, and risk stratification for MS.
Treatment:
- IV steroids speed recovery but don't improve final visual outcome in typical ON. The primary benefit in patients with MS-like lesions is a delay in conversion to CDMS.
- Oral prednisone alone (without prior IV treatment) is contraindicated for typical ON. It was associated with a higher rate of recurrence in the ONTT.
- Consider plasma exchange (PLEX) for severe, steroid-unresponsive atypical ON, especially in NMOSD or MOGAD.
- Early discussion about MS risk and potential DMTs: Patients with ON and MS-like lesions on MRI should be counseled about DMTs for MS.
Pitfalls:
- Misdiagnosing ON: Confusing ON with other causes of acute vision loss such as ischemic optic neuropathy, compressive optic neuropathy, or infectious optic neuropathy.
- Delaying MRI: Delaying brain MRI can miss valuable information for MS risk stratification and differential diagnosis.
- Prescribing oral steroids alone: This has been shown to increase the risk of recurrence.
- Not considering atypical ON: Failure to investigate for NMOSD or MOGAD can lead to delayed diagnosis, inappropriate treatment, and worse long-term outcomes.
- Missing Giant Cell Arteritis (GCA): In older patients, acute vision loss and pain (especially with jaw claudication, scalp tenderness) should prompt immediate investigation and treatment for GCA, which can cause permanent bilateral blindness if untreated.

Recent Updates

Guidelines:
- Evolving Diagnostic Criteria for NMOSD and MOGAD: Recent consensus criteria (e.g., 2015 International Consensus Diagnostic Criteria for NMOSD, 2023 International MOGAD Panel Consensus Criteria) provide clearer guidance for diagnosis, emphasizing serological testing.
- Updated MS Diagnostic Criteria (McDonald Criteria): The 2017 McDonald criteria allow for earlier diagnosis of MS, potentially enabling earlier initiation of DMTs.
Evidence:
- Newer DMTs for MS: A growing arsenal of highly effective DMTs for MS (e.g., cladribine, ocrelizumab, ofatumumab, ozanimod, siponimod) has broadened treatment options, particularly for highly active disease.
- Specific Treatments for NMOSD: Monoclonal antibodies targeting complement (eculizumab), B-cells (inebilizumab), or IL-6 signaling (satralizumab) have been approved, demonstrating significant efficacy in reducing NMOSD relapses.
- MOGAD Treatment Research: Ongoing research is defining optimal long-term immunosuppressive strategies for MOGAD, with IVIg, rituximab, and mycophenolate mofetil showing promise.
- Retinal Imaging Biomarkers: OCT is increasingly used as a prognostic tool in ON and MS, with specific patterns of retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thinning associated with visual outcomes and disease progression.
Controversies:
- Optimal Timing and Choice of DMT for CIS: The exact timing and choice of DMT for patients with a first ON attack (CIS) and high risk for MS but who haven't met full MS diagnostic criteria remains an area of active debate and individualized decision-making.
- Duration of Immunosuppression in MOGAD: The optimal duration of long-term immunosuppression for MOGAD, especially in children, is still being studied, given potential for spontaneous resolution in some cases but high recurrence risk in others.

Key References

Guidelines:
- Optic Neuritis Treatment Trial (ONTT): The foundational study guiding acute ON management (Beck et al., N Engl J Med. 1992;326:581-8).
- McDonald Criteria for MS Diagnosis (2017 Update): Thompson AJ et al., Lancet Neurol. 2018;17:162-73.
- International Consensus Diagnostic Criteria for NMOSD (2015): Wingerchuk DM et al., Neurology. 2015;85:177-89.
- International MOGAD Panel Consensus Criteria (2023): Banwell B et al., Ann Neurol. 2023;93:1103-15.
- American Academy of Neurology (AAN) Guidelines: Relevant guidelines for MS and other demyelinating diseases.
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / European Academy of Neurology (EAN) Guidelines: Consensus recommendations for MS management.
Studies:
- Controlled High-Dose Intravenous Methylprednisolone in Optic Neuritis (CHAMPIONS) Trial: Further exploring steroid efficacy in ON.
- NMOSD and MOGAD pivotal trials: Studies leading to the approval of specific treatments (e.g., N-MOmentum (satralizumab), PREVENT (inebilizumab), Soliris (eculizumab) for NMOSD; upcoming MOGAD trials).
Reviews:
- Recent review articles on neuro-ophthalmology, multiple sclerosis, neuromyelitis optica spectrum disorder, and MOG-antibody-associated disease published in journals such as Neurology, Annals of Neurology, Brain, Lancet Neurology, and Journal of Neuro-ophthalmology.